Chiesi Global Rare Diseases and Protalix BioTherapeutics Seek Re-examination from the EMA for the Negative Opinion for Elfabrio (pegunigalsidase alfa) Alternative Dos…

Every two weeks remains approved as a dosing regimen of Elfabrio in the EU --PARMA, Italy and CARMIEL, Israel, Nov. 03, 2025 ...
Le Lézard

Two Day Conference: Integrated Resource Planning for Today's US Power Markets (Houston, United States - Dec 9th - Dec 10th, 2025) - ResearchAndMarkets.com

The "Integrated Resource Planning for Today's Power Markets (Houston, United States - Dec 9th - Dec 10th, 2025)" training has been added to ResearchAndMarkets.com's offering. The U.S. energy system is ...

TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027

Positive end of Phase I meeting and agreement reached with FDA on pivotal study design for TSC-101 Dosed first solid tumor patients with multiplex TCR-T therapy; paused further enrollment to ...